BIOMAT Database Logo BIOMAT Database Logo

Zidovudine and HIV-2 disease. 1990

S G Dawson, and H M Chapel, and R P Eglin

UI MeSH Term Description Entries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

S G Dawson, and H M Chapel, and R P Eglin
Zidovudine in early HIV disease.
March 1993, Hospital practice (Office ed.),
S G Dawson, and H M Chapel, and R P Eglin
Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
September 1993, Journal of neurology,
S G Dawson, and H M Chapel, and R P Eglin
Zidovudine: clinical experience in symptomatic HIV disease.
January 1989, AIDS clinical review,
S G Dawson, and H M Chapel, and R P Eglin
[HIV infection. Zidovudine and 2',3'-dideoxycytidine in AIDS].
December 1988, Medizinische Monatsschrift fur Pharmazeuten,
S G Dawson, and H M Chapel, and R P Eglin
HIV antigenemia and zidovudine.
June 1988, AIDS (London, England),
S G Dawson, and H M Chapel, and R P Eglin
HIV, AIDS, and zidovudine.
March 1992, Lancet (London, England),
S G Dawson, and H M Chapel, and R P Eglin
HIV, AIDS, and zidovudine.
March 1992, Lancet (London, England),
S G Dawson, and H M Chapel, and R P Eglin
Total costs of HIV disease higher with zidovudine?
January 1992, PharmacoEconomics,
S G Dawson, and H M Chapel, and R P Eglin
Didanosine for zidovudine-intolerant patients with HIV disease.
November 1992, Lancet (London, England),
S G Dawson, and H M Chapel, and R P Eglin
Zidovudine resistant HIV.
April 1989, BMJ (Clinical research ed.),
Copied contents to your clipboard!